From blood transfusion to patient blood management: A new paradigm for patient care and cost assessment of blood transfusion practice

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages 332-338

  Leahy, M F ^a   Mukhtar, S A ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Blood product; Guideline; Patient blood management; Shortage

Indexed keywords

ERYTHROPOIETIN; IMMUNOGLOBULIN; IRON; TRANEXAMIC ACID;

ADVERSE OUTCOME; ANEMIA; ARTICLE; BLEEDING; BLOOD; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; CRYOPRECIPITATE; DEMOGRAPHY; EMERGENCY MEDICINE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; INTENSIVE CARE; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION;

AGED; ANEMIA; AUSTRALIA; BLOOD BANKS; BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; CRITICAL CARE; DISEASE MANAGEMENT; EVIDENCE-BASED PRACTICE; FERRIC COMPOUNDS; HEMATOLOGIC DISEASES; HUMANS; INAPPROPRIATE PRESCRIBING; MODELS, THEORETICAL; PATIENT-CENTERED CARE; PERIOPERATIVE CARE; PLASMA; PLATELET TRANSFUSION; POPULATION DYNAMICS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS;

EID: 84858733837     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02717.x     Document Type: Article

References (44)

1. Thomson A, Farmer S, Hofmann A, Isbister J, Shander A. Patient blood management - a new paradigm for transfusion medicine? ISBT Science Series 2009; 4: 423-35.
2. Beal RW, Isbister JP. Chapter 2. In: Blood Component Therapy in Clinical Practice. Carlton: Blackwell Scientific Publications; 1985; 11-42.
3. Health Department of Western Australia. Western Australian Patient Blood Management Project: Executive Summary. 2011. [cited 2012 Jan 21]. Available from URL:.
4. American Red Cross. Financials and Reporting. 2010 [cited 2012 Jan 21]. Available from URL:.
5. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50: 753-65.
6. Wood E. Transfusing a unit of red cells: what does it really cost? Seminars at Peter Mac; 2010 Transfusion Seminar. 2010; [cited 2012 Jan 21]. Available from URL:.
7. Australian Bureau of Statistics. Consumer price index, hospital and medical services; Australia (A2329041T). 2011. [cited 2012 Jan 21]. Available from URL:.
8. Morton J, Anastassopoulos KP, Patel ST, Lerner JH, Ryan KJ, Goss TF etal. Frequency and outcomes of blood products transfusion across procedures and clinical conditions warranting inpatient care: an analysis of the 2004 healthcare cost and utilization project nationwide inpatient sample database. Am J Med Qual 2010; 25: 289-96.
9. Shander A, Fink A, Javidroozi M, Erhard J, Farmer SL, Corwin HL etal. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev 2011; 25: 232-46.
10. National Blood Authority. Guidelines and Standards. 2012 [cited 2012 Jan 21]. Available from URL:.
11. Australian Council on Healthcare Standards. EQuIP5 Guide. 2011. Available from URL:.
12. Cobain TJ, Vamvakas EC, Wells A, Titlestad K. A survey of the demographics of blood use. Transfus Med 2007; 17: 1-15.
13. Mukhtar SA. 2010-2011. Patient Blood Management (PBM) Reporting Data System v 2.0. Office of Chief Medical Officer, Department of Health, Western Australia. [cited 2012 Jan 21]. Available from URL:.
14. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754-61.
15. Garg M, Morrison G, Friedman A, Lau A, Lau D, Gibson PR. A rapid infusion protocol is safe for total dose infusion with iron polymaltose: time for a change. Intern Med J 2011; 41: 548-54.
16. Goodnough LT, Shander A, Spivak JL, Waters JH, Friedman AJ, Carson JL etal. Detection evaluation and management of anaemia in the elective surgical patient. Anesth Analg 2005; 101: 1858-61.
17. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47: 1468-80.
18. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA etal. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
19. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E etal. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a Randomized Clinical Trial. Cancer 2012; 118: 848-55.
20. Nevo S, Fuller AK, Zahurak ML, Hartley E, Borinsky ME, Vogelsang GB. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9)/L. Transfusion 2007; 47: 1700-9.
21. Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 22: 4087-94. Epub 2004 Sep.
22. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113: 6296-303.
23. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M etal. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605-13.
24. Australian Government, Department of Health and Ageing. The Pharmaceutical Benefits Scheme. 2012 [cited 2012 Jan 21]. Available from URL:.
25. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A etal. for the International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32.
26. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230-36.
27. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW etal. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-62.
28. DeFoe GR, Ross CS, Olmsted EM, Surgenor SD, Fillinger MP, Groom RC etal. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease study group. Ann Thorac Surg 2001; 71: 769-76.
29. Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijeysundera D etal. Low hematocrit during cardiopulmonary bypass is associated with increased risk of stroke in cardiac surgery. Ann Thorac Surg 2005; 8080: 1381-7.
30. Fang WC, Helm RE, Krieger KH, Rosengart TK, DuBois WJ, Sason C etal. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation 1997; 96: 194-9.
31. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G etal. A multicenter, randomized clinical trial of transfusion requirements in critical care. Transfusion requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-17.
32. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A etal. Anaemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-1507.
33. Moskowitz DM, McCullough JN, Shander AA, Klein JJ, Bodian CA, Goldweit RS etal. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? Ann Thorac Surg 2010; 90: 451-8.
34. Weber EW, Slappendel R, Hémon Y, Mähler S, Dalén T, Rouwet E etal. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 4: 249-57.
35. Wong CJ, Vandervoort MK, Vandervoort SL, Donner A, Zou G, MacDonald JK etal. A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty. Transfusion 2007; 47: 832-41.
36. Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 2010; 113: 482-95.
37. Varghese R, Myers ML. Blood Conservation in cardiac surgery: lets get restrictive. Semin Thorac Cardiovasc Surg 2010; 22: 121-6.
38. Clinical Excellence Commission. Blood Watch Program. 2012 [cited 2012 Jan 21]. Available from URL:.
39. SA Health. Blood Safe Program. 2012 [cited 2012 Jan 21]. Available from URL:.
40. Queensland Blood Management Program. 2012 [cited 2012 Jan 21]. Available from URL:.
41. Health Department of Western Australia. Patient Blood Management. 2012 [cited 2012 Jan 21]. Available from URL:.
42. Theusinger OM, Nurnberg J, Asmis LM, Seifert B, Spahn DR. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37: 677-83.
43. Mukhtar SA, Leahy MF, Trentino K, Tovey J, Jewlachow V, Semmens JB etal. A New Platform for Patient Blood Management in WA: Translating Data and Practice to New Models of Care - Final Project Report. Western Australia: Centre for Population Health Research, Curtin University and State Health Research Advisory Council Department of Health; 2010; [cited 2012 Jan 21]. Available from URL:.
44. Wilkinson KL, Brunskill SJ, Doree C, Hopewell S, Stanworth S, Murphy MF etal. The clinical effects of red blood cell transfusions: an overview of the randomized controlled trials evidence base. Transfus Med Rev 2011; 25: 145-55.